MEA Pen Needles Market

MEA Pen Needles Market Size (2022 to 2027)

The Middle East & Africa pen needles market size is expected to reach USD 0.48 billion by 2027 from USD 0.29 billion in 2022, growing at a CAGR of 10.77% for the next five years, 2022 to 2027.

Pen needles are used to deliver the medication (such as insulin or other injectable medications) combined with injection pens. A pen needle comprises a hollow needle attached to an injection pen. Pen needles are available with varied needle lengths and are majorly utilized by diabetes patients.

Growing annual health care expenditure, increasing public & private organizations' involvement in diabetes awareness programs, and rising demand for advanced insulin delivery devices drive the growth of the Middle East & Africa pen needles market. However, limited accessibility of pen needles and lack of health care infrastructure & outdated facilities are restraining the growth of the Middle East & Africa pen needles market.

This research report on the Middle East and Africa Pen Needles Market has been segmented and sub-segmented into the following categories:

By Therapy: 

• Insulin Therapy
• GLP-1 Therapy
• Growth Hormone Therapy

By Type: 

• Standard Needle
• Safety Needle

By Needle Length: 

• 4mm
• 6mm
• 8mm
• 10mm
• 12mm

By Mode of Purchase: 

• Retail
• Non-Retail

By Country: 

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

Companies leading the MEA Pen Needles Market profiled in this report are Becton Dickinson and Company (U.S.), Novo Nordisk A/S (Denmark), Ypsomed Holding AG (Switzerland), UltiMed, Inc. (U.S.), Allison Medical, Inc. (U.S.), Owen Mumford, Ltd. (U.K.), B. Braun Melsungen (Germany), Artsana S.p.a. (Italy), HTL-STREFA S.A. (Poland), Terumo Corporation (Japan) and others.